Tech Company Financing Transactions
Encoded Therapeutics Funding Round
Encoded Therapeutics, operating out of San Francisco, raised $135 million from GV, Arch Venture Partners and Boxer Capital.
Transaction Overview
Company Name
Announced On
7/23/2020
Transaction Type
Venture Equity
Amount
$135,000,000
Round
Series D
Investors
Proceeds Purpose
Proceeds from the Series D will be used to conduct clinical trial activities including a natural history study to better understand the progression of SCN1A+ Dravet Syndrome as well as first-in-human trials for ETX101.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
341 Oyster Point Blvd.
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Website
Email Address
Overview
Encoded Therapeutics, Inc., is a biotechnology company developing precision gene therapies for a broad range of severe genetic disorders. Our mission is to realize the potential of genomics-driven precision medicine by overcoming key limitations of viral gene therapy.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Sean Nolan
Chief Executive Officer
Kartik Ramamoorthi
Chief Medical Officer
Salvador Rico
Chief Operating Officer
David Oberkofler
Chief Scientific Officer
Stephanie Tagliatela
Chief Technical Officer
Martin Moorhead
VP - Bus. Development
David McNinch
VP - Human Resources
Monique Bobadilla
VP - Manufacturing
Andrew Stober
VP - Regulatory Affairs
Nancy Boman
Browse more venture capital transactions:
Prev: 7/23/2020: Dexterity venture capital transaction
Next: 7/23/2020: CurvaFix venture capital transaction
Share this article
News on VC Transactions
We report on every notable VC transaction. All VC database entries reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs